+ Watch DARA
on My Watchlist
Improving technicals and no insider open market sales since 2008.
I could easily have red thumbed Dara if the stock had continued to rise on irrational exuberance related to Orphan Drug designation for KRN5500. Instead, hyperactive momo traders dumped the stock to look for more muppet bait. Meanwhile, Dara continues to derive all operational funding from dilution rather than product sales. Can the recidivist Dara hypers start working the bellows again? I'm sure they can.
DARA r/s split play
gut feeling only.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions